| __timestamp | CymaBay Therapeutics, Inc. | Neurocrine Biosciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 15823000 | 46425000 |
| Thursday, January 1, 2015 | 17026000 | 81491000 |
| Friday, January 1, 2016 | 15941000 | 94291000 |
| Sunday, January 1, 2017 | 18938000 | 121827000 |
| Monday, January 1, 2018 | 58124000 | 160524000 |
| Tuesday, January 1, 2019 | 83837000 | 200000000 |
| Wednesday, January 1, 2020 | 35882000 | 275000000 |
| Friday, January 1, 2021 | 64542000 | 328100000 |
| Saturday, January 1, 2022 | 67995000 | 463800000 |
| Sunday, January 1, 2023 | 80118000 | 565000000 |
| Monday, January 1, 2024 | 731100000 |
Unlocking the unknown
In the competitive world of biotechnology, innovation is the lifeblood of success. Neurocrine Biosciences, Inc. and CymaBay Therapeutics, Inc. have been at the forefront of this race, each investing heavily in research and development (R&D) over the past decade. From 2014 to 2023, Neurocrine Biosciences consistently outpaced CymaBay Therapeutics, with R&D expenses growing by an impressive 1,116%, reaching a peak in 2023. In contrast, CymaBay's R&D investment increased by 406% during the same period. This significant difference highlights Neurocrine's commitment to innovation, spending nearly four times more on R&D in 2023 compared to CymaBay. As the biotech industry continues to evolve, these investments are crucial for developing groundbreaking therapies and maintaining a competitive edge. The data underscores the importance of strategic R&D spending in driving growth and innovation in the biotech sector.
Who Prioritizes Innovation? R&D Spending Compared for AbbVie Inc. and Neurocrine Biosciences, Inc.
Research and Development Investment: Gilead Sciences, Inc. vs Neurocrine Biosciences, Inc.
Vertex Pharmaceuticals Incorporated or Neurocrine Biosciences, Inc.: Who Invests More in Innovation?
Regeneron Pharmaceuticals, Inc. vs Neurocrine Biosciences, Inc.: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for Neurocrine Biosciences, Inc. and Verona Pharma plc
Research and Development Expenses Breakdown: Neurocrine Biosciences, Inc. vs Amicus Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Neurocrine Biosciences, Inc. and Arrowhead Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Neurocrine Biosciences, Inc. and Soleno Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Neurocrine Biosciences, Inc. and Novavax, Inc.
Analyzing R&D Budgets: Sarepta Therapeutics, Inc. vs CymaBay Therapeutics, Inc.
Comparing Innovation Spending: CymaBay Therapeutics, Inc. and Viking Therapeutics, Inc.
R&D Insights: How CymaBay Therapeutics, Inc. and Perrigo Company plc Allocate Funds